Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
A. Lanas, M.A. Pérez-Aisa, F. Feu, J. Ponce, E. Saperas, S. Santolaria, Investigators of the Asociación Española de Gastroenterología (AEG), et al.
A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use.
Am J Gastroenterol, 100 (2005), pp. 1685-1693
[2.]
C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, B. Davis, et al.
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
N Engl J Med, 343 (2000), pp. 1520-1528
[3.]
T.J. Schnitzer, G.R. Burmester, E. Mysler, M.C. Hochberg, M. Doherty, E. Ehrsam, et al.
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
Lancet, 364 (2004), pp. 665-674
[4.]
D.Y. Graham, N.M. Agrawal, D.R. Campbell, M.M. Haber, C. Collis, N.L. Lukasik, et al.
Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: Results of a doubleblind, randomized, multicenter,active-and placebo-controlled study of misoprostol vs Lansoprazole.
Arch Intern Med, 162 (2002), pp. 169-175
[5.]
F.K. Chan, S.C. Chung, B.Y. Suen, Y.T. Lee, W.K. Leung, V.K. Leung, et al.
Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.
N Engl J Med, 344 (2001), pp. 967-973
[6.]
C.M. Wilcox, J. Allison, K. Benzuly, M. Borum, B. Cryer, T. Grosser, American Gastroenterological Association, et al.
Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin.
Clin Gastroenterol Hepatol, 4 (2006), pp. 1082-1089
[7.]
American College of Rheumatology Subcommittee on Osteoarthritis Guidelines.
Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update.
Arthritis Rheum, 43 (2000), pp. 1905-1915
[8.]
R.S. Bresalier, R.S. Sandler, H. Quan, J.A. Bolognese, B. Oxenius, K. Horgan, et al.
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
N Engl J Med, 352 (2005), pp. 1092-1102
[9.]
S.D. Solomon, J.J. McMurray, M.A. Pfeffer, J. Wittes, R. Fowler, P. Finn, et al.
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
N Engl J Med, 352 (2005), pp. 1071-1080
[10.]
J.A. Cairns.
The coxibs and traditional nonsteroidal anti-inflammatory drugs: a current perspective on cardiovascular risks.
Can J Cardiol, 23 (2007), pp. 125-131
[11.]
A. Lanas, R. Hunt.
Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies [review].
Ann Med, 38 (2006), pp. 415-428
[12.]
J.M. Scheiman, A.M. Fendrick.
Summing the risk of NSAID therapy.
Lancet, 369 (2007), pp. 1580-1581
Copyright © 2008. Elsevier España S.L.. Todos los derechos reservados
